Trial Profile
The Effect of Tasisulam on the CYP2C9-Mediated Metabolism of Tolbutamide: A Pharmacokinetic Interaction Study in Cancer Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Tasisulam (Primary) ; Tolbutamide
- Indications Lymphoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 12 Apr 2011 Status changed from suspended to discontinued, according to ClincalTrials.gov.
- 01 Dec 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 04 Sep 2010 New trial record